Intensive CareNCT06667310
Effects of Neutrophil/Lymphocyte, Platelet/Lymphocyte, CRP/Albumin and Lactate on Mortality in Trauma Patients Admitted to Intensive Care
An observational study of Intensive Care, run by Harran University at 1 site in Turkey (Türkiye).
Trial summary
Intensive care units are medical units where patients are closely monitored 24 hours a day due to critical health problems that threaten their lives and where rapid interventions are made when necessary. The clinical conditions of patients in these units can change rapidly. Read more about this study
- Who is it for?
- Ages 1 year to 95 years
- Conditions the study is for
- Intensive Care
- How many people
- 150 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 5 Nov 2024to 15 May 2025
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year to 95 years
- All sexes
- Child, Adult, Older adult
Study population: 1-95 age intensive care patients
Who may be able to join
- 1. All trauma patients admitted to our general intensive care unit
Who cannot join
- 1. Patients whose follow-up and treatment started and completed in the services.
- 2. Patients whose data is missing or whose data cannot be accessed.
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Veli Fahri Pehlivan
Karaköprü, Şanliurfa, 63100
About this study
Official title: Evaluatıon Of The Effect Of Neutrophıl/Lymphocyte, Platelet/Lymphocyte, Crp/Albumın, Base Defıcıt And Lactate Levels On Mortalıty Durıng The Admıssıon Of Trauma Patıents To Intensıve Care
Intensive care units are medical units where patients are closely monitored 24 hours a day due to critical health problems that threaten their lives and where rapid interventions are made when necessary. The clinical conditions of patients in these units can change rapidly. There are many studies in the literature indicating that inflammation indicators such as Neutrophil/Lymphocyte, Platelet/Lymphocyte and C-Reactive Protein/Albumin ratios and blood gas values such as Lactate and Base Deficit are simple, cheap and rapid biomarkers that can provide an early idea about the clinical course of patients.
Read the detailed description
Intensive care units are medical units where patients are closely monitored 24 hours a day due to critical health problems that threaten their lives and where rapid interventions are made when necessary. The clinical conditions of patients in these units can change rapidly. There are many studies in the literature indicating that inflammation indicators such as Neutrophil/Lymphocyte, Platelet/Lymphocyte and C-Reactive Protein/Albumin ratios and blood gas values such as Lactate and Base Deficit are simple, cheap and rapid biomarkers that can provide an early idea about the clinical course of patients. The researchers aimed to evaluate the relationship between Neutrophil/Lymphocyte, Platelet/Lymphocyte and C-Reactive Protein/Albumin ratios and biomarkers such as Lactate and Base Deficit with the clinical course and survival of trauma patients admitted to the ICU and to see the compatibility of our data with the existing literature.
- Conditions
- Intensive Care
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary outcome
- LACTATE LEVELS RATİO MEASUREMENT
Measured: one day
Secondary outcomes (1)
seconary outcome
The effect of these measurements on mortality
Measured: one day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Oct 2024
- Study start5 Nov 2024
- Primary completion10 Jan 2025
- Study completion15 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Intensive CareStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Other
- Enrolment
- 150 participants (actual)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- Harran University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Veli Fahri Pehlivan, Harran University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06667310
- Sponsor's protocol ID
- Hasan
- Status last verified
- May 2025
- First submitted
- 25 Oct 2024
- Last updated
- 15 May 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluatıon Of The Effect Of Neutrophıl/Lymphocyte, Platelet/Lymphocyte, Crp/Albumın, Base Defıcıt And Lactate Levels On Mortalıty Durıng The Admıssıon Of Trauma Patıents To Intensıve Care
- ClinicalTrials.gov ID
- NCT06667310
- Acronym / sponsor ID
- Hasan
- Conditions
- Intensive Care
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 150 participants (actual)
- Lead sponsor
- Harran UniversityUniversity, hospital or other
- Study start
- 5 Nov 2024 (actual)
- Primary completion
- 10 Jan 2025 (actual)
- Study completion
- 15 May 2025 (actual)
- First posted
- 31 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Intensive care units are medical units where patients are closely monitored 24 hours a day due to critical health problems that threaten their lives and where rapid interventions are made when necessary. The clinical conditions of patients in these units can change rapidly. There are many studies in the literature indicating that inflammation indicators such as Neutrophil/Lymphocyte, Platelet/Lymphocyte and C-Reactive Protein/Albumin ratios and blood gas values such as Lactate and Base Deficit are simple, cheap and rapid biomarkers that can provide an early idea about the clinical course of patients.
Detailed description
Intensive care units are medical units where patients are closely monitored 24 hours a day due to critical health problems that threaten their lives and where rapid interventions are made when necessary. The clinical conditions of patients in these units can change rapidly. There are many studies in the literature indicating that inflammation indicators such as Neutrophil/Lymphocyte, Platelet/Lymphocyte and C-Reactive Protein/Albumin ratios and blood gas values such as Lactate and Base Deficit are simple, cheap and rapid biomarkers that can provide an early idea about the clinical course of patients. The researchers aimed to evaluate the relationship between Neutrophil/Lymphocyte, Platelet/Lymphocyte and C-Reactive Protein/Albumin ratios and biomarkers such as Lactate and Base Deficit with the clinical course and survival of trauma patients admitted to the ICU and to see the compatibility of our data with the existing literature.
Study design
- Observational model
- Other
- Time perspective
- Other
- Target follow-up
- 1 Year
Who may qualify
- Ages
- 1 year to 95 years
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- 1-95 age intensive care patients
Key inclusion criteria (1 listed)
- 1. All trauma patients admitted to our general intensive care unit
Key exclusion criteria (2 listed)
- 1. Patients whose follow-up and treatment started and completed in the services.
- 2. Patients whose data is missing or whose data cannot be accessed.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Primary outcome
Time frame: one day
1. LACTATE LEVELS RATİO MEASUREMENT
1 secondary outcome
seconary outcome
Time frame: one day
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 May 2025.
Related trials for Intensive Care
Recruiting
Effect of Rutin and Vitamin C on Outcomes in Adults With Sepsis Admitted to the Intensive Care Unit
Sepsis
Not yet recruitingObservational study
CAROTID DOPPLER AND CEREBRAL OXIMERY IN POST CARDIAC ARREST ICU PATIENTS
Cardiac Arrest (CA), Carotid Doppler
Active, not recruitingObservational study
Potential Impact of the Use of the Application VentilO
Mechanical Ventilation Complication
Not yet recruitingPhase 4
Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia
Community Acquired Pneumonia (CAP)
RecruitingPhase 3
Canadian Critical Care Comparative Effectiveness Platform
Intensive Care Unit ICU, Vasopressor
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Intensive Care, run by Harran University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary outcome (time frame: one day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2025.